Advancing Upper Limb Motor Recovery in Acute Ischemic Stroke With Transcutaneous Auricular Vagus Nerve Stimulation.

Arch Phys Med RehabilMay 13, 2026 (epub)
Clinical ResearchNeurologyPhysical Medicine & Rehabilitation

Baoshan Xu, Yihui Cheng, Xinyue Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in 60 patients with acute ischemic stroke. The taVNS group showed significant improvements in the Fugl-Meyer Assessment for Upper Extremity and Modified Barthel Index, along with a notable reduction in the National Institutes of Health Stroke Scale compared to controls (all P<.05).

Key findings

  • The taVNS group showed significant improvements in FMA-UE and MBI scores postintervention (P<.05).
  • A significant reduction in NIHSS was observed in the taVNS group compared to controls (P<.05).
  • Heart rate and blood pressure remained stable throughout the treatment period with no significant changes (P>.05).

Why it matters

The findings suggest that taVNS may enhance motor recovery and functional independence in patients with acute ischemic stroke, potentially improving rehabilitation outcomes when used alongside conventional therapies.

Source

PubMed · PMID 42134674

Published in Arch Phys Med Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.